Review




Structured Review

MedSciNet UK Ltd randomisation facility
Schedule of participant enrolment, interventions and assessments in the trial. PARCA-R Parent Report of Cognitive Abilities, Revised, SAE serious adverse event. 1 Screening to be conducted of all women suspected of being eligible for the study. 2 Delivery to be commenced within 48 hours of <t>randomisation</t> for women randomised to the planned delivery group. 3 Eligibility for study to be assessed from blood pressure recorded at the time the diagnosis of pre-eclampsia. 4 Blood systolic pressure reading within the 48 hours prior to randomisation to be recorded. 5 Highest systolic blood pressure recorded between randomisation and delivery to be recorded. 6 Highest systolic blood pressure recorded between delivery and discharge to be recorded. 7 Haematology and/or Biochemistry results that contributed to diagnosis of pre-eclampsia to be recorded. 8 The most recent Haematology and/or Biochemistry results prior to randomisation to be recorded. 9 Abnormal Haematology/ Biochemistry results from randomisation to discharge to be recorded at discharge. 10 Serious Adverse Events (SAEs) to be recorded from randomisation to post-natal discharge. Only unexpected SAEs to be reported. 11 Brief details of anti-hypertensive and medication for induction will be recorded; all other concomitant medication will only be recorded in the event that an unexpected Serious Adverse Event is reported. 12 EQ-5D-5L to be given to the participant to complete immediately after randomisation
Randomisation Facility, supplied by MedSciNet UK Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+randomisation+system+trust/randomisation+facility/pmc06350286-125-6-12
Average 90 stars, based on 1 article reviews
randomisation facility - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "Planned delivery or expectant management for late preterm pre-eclampsia: study protocol for a randomised controlled trial (PHOENIX trial)"

Article Title: Planned delivery or expectant management for late preterm pre-eclampsia: study protocol for a randomised controlled trial (PHOENIX trial)

Journal: Trials

doi: 10.1186/s13063-018-3150-1

Schedule of participant enrolment, interventions and assessments in the trial. PARCA-R Parent Report of Cognitive Abilities, Revised, SAE serious adverse event. 1 Screening to be conducted of all women suspected of being eligible for the study. 2 Delivery to be commenced within 48 hours of randomisation for women randomised to the planned delivery group. 3 Eligibility for study to be assessed from blood pressure recorded at the time the diagnosis of pre-eclampsia. 4 Blood systolic pressure reading within the 48 hours prior to randomisation to be recorded. 5 Highest systolic blood pressure recorded between randomisation and delivery to be recorded. 6 Highest systolic blood pressure recorded between delivery and discharge to be recorded. 7 Haematology and/or Biochemistry results that contributed to diagnosis of pre-eclampsia to be recorded. 8 The most recent Haematology and/or Biochemistry results prior to randomisation to be recorded. 9 Abnormal Haematology/ Biochemistry results from randomisation to discharge to be recorded at discharge. 10 Serious Adverse Events (SAEs) to be recorded from randomisation to post-natal discharge. Only unexpected SAEs to be reported. 11 Brief details of anti-hypertensive and medication for induction will be recorded; all other concomitant medication will only be recorded in the event that an unexpected Serious Adverse Event is reported. 12 EQ-5D-5L to be given to the participant to complete immediately after randomisation
Figure Legend Snippet: Schedule of participant enrolment, interventions and assessments in the trial. PARCA-R Parent Report of Cognitive Abilities, Revised, SAE serious adverse event. 1 Screening to be conducted of all women suspected of being eligible for the study. 2 Delivery to be commenced within 48 hours of randomisation for women randomised to the planned delivery group. 3 Eligibility for study to be assessed from blood pressure recorded at the time the diagnosis of pre-eclampsia. 4 Blood systolic pressure reading within the 48 hours prior to randomisation to be recorded. 5 Highest systolic blood pressure recorded between randomisation and delivery to be recorded. 6 Highest systolic blood pressure recorded between delivery and discharge to be recorded. 7 Haematology and/or Biochemistry results that contributed to diagnosis of pre-eclampsia to be recorded. 8 The most recent Haematology and/or Biochemistry results prior to randomisation to be recorded. 9 Abnormal Haematology/ Biochemistry results from randomisation to discharge to be recorded at discharge. 10 Serious Adverse Events (SAEs) to be recorded from randomisation to post-natal discharge. Only unexpected SAEs to be reported. 11 Brief details of anti-hypertensive and medication for induction will be recorded; all other concomitant medication will only be recorded in the event that an unexpected Serious Adverse Event is reported. 12 EQ-5D-5L to be given to the participant to complete immediately after randomisation

Techniques Used: Biomarker Discovery

Related Articles

other:

Article Title: Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial
Article Snippet: Randomisation was provided by a secure, web-based randomisation program (MedSciNet, Stockholm, Sweden) and extensively checked for balance and predictability by the trial statistician (PTS) before initiating the trial.


Article Title: Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial
Article Snippet: Randomisation was managed via a secure web-based randomisation program provided by MedSciNet (London, UK), with minimisation to balance study group assignments according to maternal age (<30 years vs ≥30 years), body-mass index (BMI; <35 kg/m 2 vs ≥35 kg/m 2 ), previous parity (nulliparous women vs parous women), gestational age (<70 days vs ≥70 days), amount of bleeding (PBAC score; ≤2 vs ≥3), and randomising centre.

Blocking Assay:

Article Title: Self-start HIV postexposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy.
Article Snippet: .. Randomisation allocation was determined using block randomisation via the MedSciNet system. ..



Similar Products

90
Tayside Pharmaceuticals web-based randomisation system trust
Web Based Randomisation System Trust, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+randomisation+system+trust/web+based+randomisation+system/pmc11709295__pone__0306163__s002-193-17-23
Average 90 stars, based on 1 article reviews
web-based randomisation system trust - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Tayside Pharmaceuticals web-based tayside randomisation system trust
Web Based Tayside Randomisation System Trust, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+randomisation+system+trust/web+based+randomisation+system/pmc04449962-138-3-2
Average 90 stars, based on 1 article reviews
web-based tayside randomisation system trust - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results